SCHEMBL13290779

SCHEMBL13290779

O=C(O)c1ccc2oc(C(=O)Nc3ccc(Cl)cn3)c(NC(=O)[C@H]3CC[C@H](C(=O)N4CCOCC4)CC3)c2n1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 8/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ DEGS1 O15121 1/20 0.38
▸ MAPK1 P28482 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ GAA P10253 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290792 0.94 F10 (0.41) F10SMN1; SMN2DEGS1MAPK1LMNA
SCHEMBL2955243 0.94 F10 (0.42) F10SMN1; SMN2DEGS1MAPK1LMNA
SCHEMBL2955245 0.94 F10 (0.42) F10SMN1; SMN2DEGS1MAPK1LMNA
SCHEMBL13290773 0.92 F10 (0.41) F10SMN1; SMN2DEGS1MAPK1LMNA
SCHEMBL13290966 0.88 F10 (0.41) F10SMN1; SMN2DEGS1MAPK1LMNA
SCHEMBL13290769 0.88 SMN1; SMN2 (0.44) F10SMN1; SMN2DEGS1MAPK1LMNA
SCHEMBL2945559 0.87 F10 (0.40) F10SMN1; SMN2DEGS1MAPK1LMNA
SCHEMBL2945560 0.87 F10 (0.40) F10SMN1; SMN2DEGS1MAPK1LMNA
SCHEMBL2944993 0.87 F10 (0.41) F10SMN1; SMN2DEGS1MAPK1LMNA
SCHEMBL2944997 0.87 F10 (0.41) F10SMN1; SMN2DEGS1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 F10 4/4885SMN1; SMN2 4447/4885DEGS1 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback